CSL Behring Patent-Cliff Exposure & CMS Drug Spending Portfolio

CSL Behring (US): 15 reconciled FDA prescription therapies, $1.34B 2024 CMS Part D & Medicaid spend, and 89 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies15
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$1.34B
2024 Medicare Part D Spend$840.5M
2024 Medicaid Spend$497.7M
California HCAI SB 17 Filings89 WAC filings (max 25.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.